The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Gene Therapy Bioassays Market Over The Forecast Period?

The gene therapy bioassays market size has witnessed rapid growth in recent years. It is anticipated to expand from $1.21 billion in 2025 to $1.41 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 16.5%. The historical growth of this market is attributable to the proliferation of gene therapy research programs, an increase in viral vector manufacturing, heightened clinical trial activity, the embrace of standardized bioassay protocols, and increasing regulatory scrutiny on gene therapy products.

The gene therapy bioassays market is anticipated to undergo significant expansion in the coming years. Its size is projected to reach $2.62 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.7%. This expansion is primarily driven by the increasing commercialization of gene therapies, a rising demand for high-throughput bioassay solutions, the broadening field of personalized genetic medicine, growing investments in advanced cell and gene therapy pipelines, and an increased emphasis on assay automation and reproducibility. Noteworthy trends during this period include a greater adoption of cell-based potency assays, an escalating demand for viral vector characterization tests, the wider use of automated bioassay platforms, the growth of regulatory-compliant assay validation, and an enhanced focus on functional gene expression analysis.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33119&type=smp

Which Significant Factors Are Encouraging Growth In The Gene Therapy Bioassays Market?

The growing number of gene therapy clinical trials is projected to fuel expansion in the gene therapy bioassays market. These trials critically assess the safety, effectiveness, and biological function of gene-based treatments in human subjects. Their proliferation is a result of intensified research and development efforts and increased investment from biopharmaceutical companies striving to meet unmet medical needs through innovative genetic therapies. Gene therapy bioassays are essential for clinical development, providing crucial analytical tests to evaluate biological activity, potency, safety, and mechanism of action at each development stage, with regulatory scrutiny heightening as programs advance through clinical phases. For instance, in January 2026, the Bioindustry Association (BIA), a UK-based national trade association, reported that the UK had 193 ongoing advanced therapy clinical trials, with over 80% focusing on gene therapies. Therefore, the surge in gene therapy clinical trials is a key driver for the growth of the gene therapy bioassays market.

What Segment Types Are Included In The Gene Therapy Bioassays Market Analysis?

The gene therapy bioassays market covered in this report is segmented –

1) By Product Type: Cell-Based Assays; Viral Vector-Based Assays; Non-Viral Vector-Based Assays; Other Product Types

2) By Service Type: Assay Development Services; Assay Validation Services; Quality Control Testing Services; Regulatory Support Services; Data Analysis And Reporting Services; Custom Bioassay Design Services

3) By Application: Research And Development; Clinical Testing; Quality Control; Other Applications

4) By End User: Biotechnology Companies; Pharmaceutical Companies; Contract Research Organizations; Academic And Research Institutes; Regulatory Laboratories

Subsegments:

1) By Cell-Based Assays: Reporter Gene Expression Assays; Cell Viability And Cytotoxicity Assays; Transduction Efficiency Assays; Functional Potency Cell Assays; Cellular Uptake And Localization Assays

2) By Viral Vector-Based Assays: Adeno Associated Virus Vector Assays; Lentiviral Vector Characterization Assays; Retroviral Vector Titer Assays; Vector Genome Integrity Assays; Infectivity And Transduction Assays

3) By Non-Viral Vector-Based Assays: Plasmid Deoxyribonucleic Acid Delivery Assays; Lipid Nanoparticle Transfection Assays; Polymeric Carrier Efficiency Assays; Physical Gene Delivery Evaluation Assays; Non Viral Vector Stability Assays

4) By Other Product Types: Immunogenicity Assessment Assays; Biodistribution And Persistence Assays; Safety And Toxicity Bioassays; Analytical Method Development Assays; Custom Gene Therapy Bioassays

Which Trends Are Shaping The Gene Therapy Bioassays Market Landscape?

Major companies operating in the gene therapy bioassays market are increasingly integrating artificial intelligence and machine learning into bioassay analysis, exemplified by AI-enabled digital PCR data interpretation. This approach seeks to improve accuracy, diminish experimental variability, accelerate result generation, and optimize the assessment of therapeutic efficacy and safety during gene therapy development. AI-enabled dPCR data interpretation leverages advanced algorithms to automate result analysis, distinguish true signals from background noise, and precisely quantify viral genomes or vector copy number with reduced human intervention. For instance, in April 2025, QIAGEN N.V., a Germany-based molecular diagnostics company, launched an expansion of its QIAcuity lentivirus solutions, which included the QIAcuity RCL Quant Kit and CGT dPCR assays. These solutions offer algorithm-driven absolute quantification, compatibility for multiplex and singleplex assays for vector genome and vector copy number analysis, and software-assisted data analysis workflows designed to aid regulatory-compliant decision-making in gene therapy bioassay applications.

Who Are The Key Market Participants In The Gene Therapy Bioassays Market?

Major companies operating in the gene therapy bioassays market are Boehringer Ingelheim BioXcellence, AGC Biologics, ICON plc, Lonza Group AG, SGS SA, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc., Catalent Inc, Recipharm AB, KBI Biopharma, Syngene International Limited, QPS Holdings LLC, BioAgilytix Labs (operationally independent CRO), Oxford Biomedica plc, Viralgen Vector S.L., ProtaGene Inc., Center for Breakthrough Medicines, RoslinCT, Immunologix Labs, Genezen Laboratories

Access The Complete Gene Therapy Bioassays Market Report:

https://www.thebusinessresearchcompany.com/report/gene-therapy-bioassays-market-report

Which Region Commands The Largest Share Of The Gene Therapy Bioassays Market?

North America was the largest region in the gene therapy bioassays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy bioassays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Gene Therapy Bioassays Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model